Speaker(s): 

Kelly Schiabor Barrett, PhD, Senior Staff Scientist, Helix, Discloses the following: Helix ["Employment Affiliation"]
Matthew Levy, PhD, Staff Research Scientist, Helix, Discloses the following: Helix ["Employment Affiliation"]
 
 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 
  1. Describe how linked genomic and EHR data can be used to measure the real-world impact of established genetic interventions, including population screening programs and pharmacogenomics.
  2. Identify examples of novel genetic associations with clinical actionability, including variant-specific treatment selection, that have emerged from clinicogenomic datasets.
  3. Explain how a clinicogenomic dataset can be used to both build and prospectively validate genetic risk tools for conditions where direct biomarker measurement is unavailable or underutilized.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Juliann Savatt, MS, LCGC, Melissa Kelly, MS, LCGC, Marc Williams, MD, and Cara McCormick, MPH have no identified disclosures. 
 
CE Committee Member/Content Reviewers have nothing to disclose: Christen Mowad, MD, Alison Mowery, DNP, CRNP
 
Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session:

None
Session date: 
09/14/2026 - 12:00pm to 1:00pm EDT
Location: 
Virtual via Microsoft Teams
Danville, PA 17822
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation Credit
Please login or register to take this course.